Stockscreener 앱 받기
29.31
0.88%
-0.21
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze Therapeutics Inc. recovery potential after sell offPortfolio Risk Summary & Fast Entry Momentum Alerts - newser.com
Pattern recognition hints at Maze Therapeutics Inc. upsideWeekly Trade Review & Long-Term Safe Investment Plans - newser.com
Does Maze Therapeutics Inc. qualify in momentum factor screeningNew Guidance & Verified Momentum Stock Watchlist - newser.com
Developing predictive dashboards with Maze Therapeutics Inc. dataJuly 2025 Opening Moves & Advanced Technical Signal Analysis - newser.com
Will Maze Therapeutics Inc. outperform the marketPortfolio Update Report & Verified Momentum Watchlists - newser.com
What is the fair value of Maze Therapeutics Inc. stock nowJuly 2025 Levels & Precise Buy Zone Identification - newser.com
Can Maze Therapeutics Inc. stock beat market expectations this quarterPortfolio Profit Report & Real-Time Buy Zone Alerts - newser.com
Why Maze Therapeutics Inc. is moving todayWeekly Profit Recap & Verified High Yield Trade Plans - newser.com
Can Maze Therapeutics Inc. stock deliver sustainable ROEJuly 2025 Action & Real-Time Stock Price Movement Reports - nchmf.gov.vn
Is Maze Therapeutics Inc. stock a top momentum playTrade Exit Summary & Community Consensus Stock Picks - nchmf.gov.vn
Will Maze Therapeutics Inc. stock rally after Fed decisionsQuarterly Market Review & Technical Entry and Exit Alerts - nchmf.gov.vn
What drives Maze Therapeutics Inc stock priceDividend Growth Stocks & Analyze Your Portfolio Risk in Seconds - earlytimes.in
Portfolio Update: Will Maze Therapeutics Inc. stock benefit from AI adoptionMarket Volume Report & Verified Momentum Watchlists - nchmf.gov.vn
Will Maze Therapeutics Inc. stock benefit from AI adoptionPortfolio Return Summary & Verified Chart Pattern Signals - nchmf.gov.vn
ETFs Investing in Maze Therapeutics, Inc. Stocks - TradingView
Weiss Ratings Reaffirms "Sell (D)" Rating for Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Can a trend reversal in Maze Therapeutics Inc. lead to recovery2025 Fundamental Recap & Capital Protection Trade Alerts - newser.com
How to use a screener to detect Maze Therapeutics Inc. breakoutsWall Street Watch & Free Daily Entry Point Trade Alerts - newser.com
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Forecast to 2035 Featuring Amicus Therapeutics, Astellas, BioMarin, Maze Therapeutics, Oxyrane ParasailResearchAndMarkets.com - The AI Journal
Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year HighWhat's Next? - MarketBeat
Maze Therapeutics Appoints Herve Hoppenot as Board Chairman - MarketScreener
What technical models suggest about Maze Therapeutics Inc.’s comeback2025 Major Catalysts & Long Hold Capital Preservation Plans - newser.com
Maze Therapeutics appoints Hervé Hoppenot as chairman of the board - Investing.com
Maze Therapeutics Appoints Hervé Hoppenot as Chairman - TipRanks
Maze Therapeutics appoints Hervé Hoppenot as board chairman - Investing.com India
Maze Therapeutics appoints Hervé Hoppenot as board chairman By Investing.com - Investing.com Australia
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors - GlobeNewswire
Detecting price anomalies in Maze Therapeutics Inc. with AI2025 Sector Review & Growth Focused Stock Pick Reports - newser.com
Predicting Maze Therapeutics Inc. trend using moving averages2025 Top Decliners & Verified Swing Trading Watchlist - newser.com
Maze Therapeutics (MAZE): Assessing Current Valuation Following a 78% Monthly Share Price Surge - Sahm
Maze Therapeutics (MAZE): Assessing Valuation After 78% 30-Day Share Price Surge - Yahoo Finance
0.64%
0.21%
자본화:
|
볼륨(24시간):